JP7046015B2 - ジカウイルス感染の治療のための方法及び組成物 - Google Patents

ジカウイルス感染の治療のための方法及び組成物 Download PDF

Info

Publication number
JP7046015B2
JP7046015B2 JP2018566196A JP2018566196A JP7046015B2 JP 7046015 B2 JP7046015 B2 JP 7046015B2 JP 2018566196 A JP2018566196 A JP 2018566196A JP 2018566196 A JP2018566196 A JP 2018566196A JP 7046015 B2 JP7046015 B2 JP 7046015B2
Authority
JP
Japan
Prior art keywords
dose
zika virus
day
compound
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018566196A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019507195A (ja
JP2019507195A5 (enExample
Inventor
バブー，ヤーラガッダ・エス
コティアン，プラビン・エル
バンティア，シャンタ
Original Assignee
バイオクライスト ファーマシューティカルズ， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by バイオクライスト ファーマシューティカルズ， インコーポレイテッド filed Critical バイオクライスト ファーマシューティカルズ， インコーポレイテッド
Publication of JP2019507195A publication Critical patent/JP2019507195A/ja
Publication of JP2019507195A5 publication Critical patent/JP2019507195A5/ja
Application granted granted Critical
Publication of JP7046015B2 publication Critical patent/JP7046015B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2018566196A 2016-03-06 2017-03-06 ジカウイルス感染の治療のための方法及び組成物 Active JP7046015B2 (ja)

Applications Claiming Priority (15)

Application Number Priority Date Filing Date Title
US201662304317P 2016-03-06 2016-03-06
US62/304,317 2016-03-06
US201662324180P 2016-04-18 2016-04-18
US62/324,180 2016-04-18
US201662368111P 2016-07-28 2016-07-28
US62/368,111 2016-07-28
US201662370697P 2016-08-03 2016-08-03
US62/370,697 2016-08-03
US201662411867P 2016-10-24 2016-10-24
US62/411,867 2016-10-24
US201662414466P 2016-10-28 2016-10-28
US62/414,466 2016-10-28
US201762462852P 2017-02-23 2017-02-23
US62/462,852 2017-02-23
PCT/US2017/020961 WO2017155886A1 (en) 2016-03-06 2017-03-06 Methods and compositions for treatment of zika virus infection

Publications (3)

Publication Number Publication Date
JP2019507195A JP2019507195A (ja) 2019-03-14
JP2019507195A5 JP2019507195A5 (enExample) 2020-04-16
JP7046015B2 true JP7046015B2 (ja) 2022-04-01

Family

ID=59789791

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018566196A Active JP7046015B2 (ja) 2016-03-06 2017-03-06 ジカウイルス感染の治療のための方法及び組成物

Country Status (9)

Country Link
US (3) US10512649B2 (enExample)
EP (1) EP3426659A4 (enExample)
JP (1) JP7046015B2 (enExample)
AU (1) AU2017229105B2 (enExample)
CA (1) CA3016588A1 (enExample)
MA (1) MA43812A (enExample)
MX (1) MX381542B (enExample)
TW (1) TWI767903B (enExample)
WO (1) WO2017155886A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7416445B2 (ja) * 2019-02-18 2024-01-17 株式会社栄養・病理学研究所 ブタにおけるｔ細胞の活性化度を評価する方法、ブタにおけるｔ細胞活性化を評価する剤、ブタｔ細胞活性化剤をスクリーニングする方法、ブタの病原体感染を検査する方法、及びハイブリドーマ

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013544788A (ja) 2010-10-15 2013-12-19 バイオクライスト ファーマシューティカルズ， インコーポレイテッド ポリメラーゼの阻害のための方法および組成物

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5985848A (en) 1997-10-14 1999-11-16 Albert Einstein College Of Medicine Of Yeshiva University Inhibitors of nucleoside metabolism
US6228741B1 (en) 1998-01-13 2001-05-08 Texas Instruments Incorporated Method for trench isolation of semiconductor devices
US7388002B2 (en) 2001-11-14 2008-06-17 Biocryst Pharmaceuticals, Inc. Nucleosides, preparation thereof and use as inhibitors of RNA viral polymerases
US7098334B2 (en) 2002-03-25 2006-08-29 Industrial Research Limited 4-amino-5H-pyrrolo[3,2-d]pyrimidine inhibitors of nucleoside phosphorylases and nucleosidases
US7560434B2 (en) 2004-06-22 2009-07-14 Biocryst Pharmaceuticals, Inc. AZA nucleosides, preparation thereof and use as inhibitors of RNA viral polymerases
ES2362805T3 (es) 2006-09-07 2011-07-13 Industrial Research Limited Inhibidores aminoacíclicos de nucleósido fosforilasas e hidrolasas.
MX2009002707A (es) 2006-09-11 2009-11-26 Southern Res Inst Nucleosidos de azoles y su utilizacion como inhibidores de arn y adn polimerasas virales.
TW200942243A (en) 2008-03-05 2009-10-16 Biocryst Pharm Inc Antiviral therapeutic agents

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013544788A (ja) 2010-10-15 2013-12-19 バイオクライスト ファーマシューティカルズ， インコーポレイテッド ポリメラーゼの阻害のための方法および組成物

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Antimicrobial Agents and Chemotherapy，2014年，Vol.58，p.6607-6614
Nature，2014年，Vol.508，p.402-405
VirusDis.，2016年02月20日，Vol.27, No.2，p.111-115

Also Published As

Publication number Publication date
US10512649B2 (en) 2019-12-24
US11975003B2 (en) 2024-05-07
US20210186976A1 (en) 2021-06-24
US10933066B2 (en) 2021-03-02
AU2017229105A1 (en) 2018-10-11
JP2019507195A (ja) 2019-03-14
EP3426659A4 (en) 2019-12-25
EP3426659A1 (en) 2019-01-16
WO2017155886A1 (en) 2017-09-14
US20190083496A1 (en) 2019-03-21
TW201731515A (zh) 2017-09-16
MA43812A (fr) 2018-11-28
CA3016588A1 (en) 2017-09-14
TWI767903B (zh) 2022-06-21
AU2017229105B2 (en) 2021-08-12
MX381542B (es) 2025-03-04
US20200085830A1 (en) 2020-03-19
MX2018010707A (es) 2019-03-28

Similar Documents

Publication Publication Date Title
JP5902698B2 (ja) ポリメラーゼの阻害のための方法および組成物
US20240269125A1 (en) Methods of treating coronavirus infections by co-administering an fkbp ligand and an antiviral agent
EP3854398B1 (en) Favipiravir for use in the treatment of coronavirus infection
WO2010053833A1 (en) Antiviral supplement formulations
RU2518314C2 (ru) Способ и средство активации irf-3 для лечения и профилактики заболеваний, вызываемых (+) phk-содержащими вирусами
US20240261313A1 (en) Kit for preventing or treating filovirus and flavivirus diseases
CA2945825C (en) Inhibition of flaviviruses or chikungunya viruses using retinoic acid analogues
US11975003B2 (en) Methods and compositions for treatment of Zika virus infection
CN104203228A (zh) 具有抗黄病毒的抗病毒活性的组合物
El-Kholy et al. Evaluation of testicular cytotoxicity and genotoxicity of sofosbuvir and sofosbuvir-ribavirin in the adult male albino rats
US20230218606A1 (en) Use of 4-aminoquinoline compound in treatment of coronavirus infection
Wutzler et al. Neuraminidase inhibitors in the treatment of influenza A and B–overview and case reports
WO2020092193A1 (en) Treatments for zika virus infection
CN114980885A (zh) 治疗hiv-1感染的方法
US12472197B2 (en) Methods, compositions, and dosing regimens for treatment of SARS-CoV-2 infections
US20240082208A1 (en) Antiviral pharmaceutical composition comprising steroid sulfatase inhibitor
KR20240142972A (ko) 제2형 중증 급성 호흡기 증후군 코로나바이러스 감염증의 예방 또는 치료용 약학 조성물 및 건강기능식품
KR101383373B1 (ko) 벼 지상부 추출물 또는 이로부터 분리한 플라보노리그난 화합물을 포함하는 항박테리아 또는 항바이러스 활성을 가지는 조성물
KR20210132581A (ko) 폴리포스페이트를 포함하는 코로나바이러스 감염 또는 감염 질환의 예방 또는 소독용 조성물
KR20220050432A (ko) Pmca 억제제를 포함하는 코로나바이러스 감염 또는 감염 질환의 예방 또는 소독용 조성물
WO2016089904A1 (en) Trans-clomiphene and its analogues as agents for treating or preventing filovirus diseases

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200304

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200304

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20210129

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210202

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210426

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210730

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210824

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20211105

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220210

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220222

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220322

R150 Certificate of patent or registration of utility model

Ref document number: 7046015

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250